billHR6178•Event Thursday, November 20, 2025Analyzed

Increasing Access to Lung Cancer Screening Act

Bullish

Impact5/10

$LH $DGX CVS Health ($CVS)UnitedHealth Group ($UNH)Humana ($HUM)Centene ($CNC)Molina Healthcare ($MOH)Healthcare

Summary

The Increasing Access to Lung Cancer Screening Act (HR6178) mandates no-cost lung cancer screenings and expanded tobacco cessation services under Medicaid, Medicare, and private insurance. This bill, if enacted, creates a guaranteed revenue stream for diagnostic and pharmaceutical companies, expanding their addressable market and increasing utilization.

Key Takeaways

1.HR6178 mandates expanded coverage for lung cancer screenings and tobacco cessation services under Medicaid, Medicare, and private insurance.
2.This bill, if enacted, would create a new, guaranteed revenue stream for diagnostic labs, imaging centers, and pharmaceutical companies.
3.The bill is in the early stages of the legislative process, having been referred to two committees in the House.

Market Implications

The potential enactment of HR6178 would structurally benefit diagnostic companies like Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX) by increasing demand for lung cancer screenings. Pharmaceutical companies providing cessation aids would also see an expanded market. Health insurers such as UnitedHealth Group Incorporated ($UNH), Humana Inc. ($HUM), Centene Corporation ($CNC), and Molina Healthcare, Inc. ($MOH) would face increased coverage mandates, but also potentially benefit from improved population health. CVS Health Corporation ($CVS) could see increased demand for related services and products. The current market performance of these companies shows varied trends, with $LH, $DGX, $UNH, $HUM, $CNC, and $MOH showing positive 7-day changes, while $CVS is up 6.96% over 7 days but down over 30 days, and $MCK is down over both periods. The bill's early stage means no immediate market impact is directly attributable, but the long-term implications are positive for companies involved in screening and cessation services.

Full Analysis

The Increasing Access to Lung Cancer Screening Act (HR6178) was introduced in the House of Representatives on November 20, 2025, and subsequently referred to the Committee on Energy and Commerce, and the Committee on Ways and Means. The bill, sponsored by Rep. Castor, Kathy [D-FL-14] with 6 cosponsors, is in its early stages of the legislative process. The bill mandates coverage for annual lung cancer screenings without prior authorization under Medicaid, Medicare, and private health insurance for individuals meeting U.S. Preventive Services Task Force guidelines. It also expands Medicaid coverage for counseling and pharmacotherapy for tobacco cessation. While the bill does not specify a direct funding amount, it establishes a new coverage requirement that would lead to increased utilization of screening and cessation services, effectively expanding the market for providers of these services. The financial mechanism is through mandated insurance coverage, meaning the costs would be borne by government programs (Medicaid, Medicare) and private insurers. Structural beneficiaries include diagnostic imaging centers and laboratories that perform lung cancer screenings, such as Labcorp Holdings Inc. ($LH) and Quest Diagnostics Incorporated ($DGX). Pharmaceutical companies providing smoking cessation aids would also benefit. Health insurers like UnitedHealth Group Incorporated ($UNH), Humana Inc. ($HUM), Centene Corporation ($CNC), and Molina Healthcare, Inc. ($MOH) would see increased payouts for these mandated services, but also potentially benefit from improved long-term health outcomes for their members. CVS Health Corporation ($CVS), with its pharmacy and MinuteClinic services, could also see increased demand for cessation products and related health services. McKesson Corporation ($MCK) as a pharmaceutical distributor would also see increased volume for cessation aids. Recent market data shows varied performance among potentially affected companies. Labcorp Holdings Inc. ($LH) is currently at $274.39, up 2.84% over 7 days and 1.75% over 30 days. Quest Diagnostics Incorporated ($DGX) is at $199.75, up 1.92% over 7 days and 0.27% over 30 days. CVS Health Corporation ($CVS) is at $76.82, up 6.96% over 7 days but down 1.41% over 30 days. UnitedHealth Group Incorporated ($UNH) is at $303.95, up 12.33% over 7 days and 6.1% over 30 days. Humana Inc. ($HUM) is at $191.72, up 10.57% over 7 days and 7.01% over 30 days. Centene Corporation ($CNC) is at $35.79, up 9.32% over 7 days but down 18.01% over 30 days. Molina Healthcare, Inc. ($MOH) is at $142.28, up 6.74% over 7 days but down 1.52% over 30 days. McKesson Corporation ($MCK) is at $862.73, down 0.3% over 7 days and 6.15% over 30 days. The bill's early stage means any market reaction is speculative, but the long-term implications for these sectors are positive if the bill progresses. As of 2026-04-07, the bill remains in committee. The next steps involve committee consideration, potential amendments, and a vote in the House, followed by Senate consideration and presidential assent. Given its early stage, the timeline for potential enactment extends into the future.